Nomura (NMR) Competitors $5.98 +0.10 (+1.77%) As of 01/17/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NMR vs. ARES, HOOD, OWL, TPL, VICI, BAM, TPG, CG, JEF, and DOCShould you be buying Nomura stock or one of its competitors? The main competitors of Nomura include Ares Management (ARES), Robinhood Markets (HOOD), Blue Owl Capital (OWL), Texas Pacific Land (TPL), VICI Properties (VICI), Brookfield Asset Management (BAM), TPG (TPG), The Carlyle Group (CG), Jefferies Financial Group (JEF), and Healthpeak Properties (DOC). These companies are all part of the "trading" industry. Nomura vs. Ares Management Robinhood Markets Blue Owl Capital Texas Pacific Land VICI Properties Brookfield Asset Management TPG The Carlyle Group Jefferies Financial Group Healthpeak Properties Nomura (NYSE:NMR) and Ares Management (NYSE:ARES) are both large-cap finance companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk. Does the media refer more to NMR or ARES? In the previous week, Ares Management had 14 more articles in the media than Nomura. MarketBeat recorded 15 mentions for Ares Management and 1 mentions for Nomura. Nomura's average media sentiment score of 0.92 beat Ares Management's score of 0.63 indicating that Nomura is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nomura 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ares Management 6 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, NMR or ARES? Nomura has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Ares Management has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Which has preferable earnings and valuation, NMR or ARES? Nomura has higher revenue and earnings than Ares Management. Nomura is trading at a lower price-to-earnings ratio than Ares Management, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNomura$10.82B1.64$1.14B$0.5910.14Ares Management$3.63B16.52$474.33M$2.1788.34 Is NMR or ARES a better dividend stock? Nomura pays an annual dividend of $0.27 per share and has a dividend yield of 4.5%. Ares Management pays an annual dividend of $3.72 per share and has a dividend yield of 1.9%. Nomura pays out 45.8% of its earnings in the form of a dividend. Ares Management pays out 171.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Nomura is clearly the better dividend stock, given its higher yield and lower payout ratio. Is NMR or ARES more profitable? Ares Management has a net margin of 12.51% compared to Nomura's net margin of 6.91%. Ares Management's return on equity of 19.89% beat Nomura's return on equity.Company Net Margins Return on Equity Return on Assets Nomura6.91% 7.93% 0.48% Ares Management 12.51%19.89%3.95% Do institutionals & insiders have more ownership in NMR or ARES? 15.1% of Nomura shares are held by institutional investors. Comparatively, 50.0% of Ares Management shares are held by institutional investors. 0.0% of Nomura shares are held by insiders. Comparatively, 41.9% of Ares Management shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community favor NMR or ARES? Ares Management received 360 more outperform votes than Nomura when rated by MarketBeat users. Likewise, 68.70% of users gave Ares Management an outperform vote while only 53.86% of users gave Nomura an outperform vote. CompanyUnderperformOutperformNomuraOutperform Votes23753.86% Underperform Votes20346.14% Ares ManagementOutperform Votes59768.70% Underperform Votes27231.30% Do analysts prefer NMR or ARES? Ares Management has a consensus target price of $171.92, indicating a potential downside of 10.32%. Given Ares Management's stronger consensus rating and higher possible upside, analysts plainly believe Ares Management is more favorable than Nomura.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nomura 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Ares Management 0 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.62 SummaryAres Management beats Nomura on 15 of the 20 factors compared between the two stocks. Get Nomura News Delivered to You Automatically Sign up to receive the latest news and ratings for NMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMR vs. The Competition Export to ExcelMetricNomuraSecurity brokers & dealers IndustryFinance SectorNYSE ExchangeMarket Cap$17.78B$32.59B$11.78B$19.94BDividend Yield4.78%2.40%6.02%3.71%P/E Ratio10.1417.9725.2441.41Price / Sales1.646.2628.3616.25Price / Cash10.5119.6117.2619.84Price / Book0.752.862.655.76Net Income$1.14B$932.00M$1.04B$993.25M7 Day Performance7.05%6.65%2.92%3.12%1 Month Performance4.43%2.69%0.91%4.75%1 Year Performance20.89%44.96%14.70%18.83% Nomura Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRNomura4.2741 of 5 stars$5.98+1.8%N/A+21.0%$17.78B$10.82B10.1426,850ARESAres Management4.5627 of 5 stars$175.68+0.4%$172.33-1.9%+64.6%$55.00B$5.08B80.962,550HOODRobinhood Markets3.8609 of 5 stars$38.98-2.7%$42.47+8.9%+349.6%$34.46B$2.41B66.072,200Analyst ForecastInsider TradeOptions VolumeGap DownOWLBlue Owl Capital2.321 of 5 stars$22.35-0.9%$24.10+7.8%+57.2%$33.38B$2.16B131.48540Analyst ForecastTPLTexas Pacific Land1.0206 of 5 stars$1,317.58+1.3%$694.17-47.3%+184.2%$30.27B$686.70M67.60100Positive NewsVICIVICI Properties4.8547 of 5 stars$28.65+1.6%$34.25+19.5%-4.0%$30.20B$3.81B10.6120BAMBrookfield Asset Management4.1704 of 5 stars$51.50-1.1%$54.46+5.7%+42.3%$22.82B$522M45.582,400TPGTPG4.148 of 5 stars$62.22-0.3%$63.00+1.3%+66.7%$22.71B$2.47B-182.991,850Analyst ForecastCGThe Carlyle Group4.5113 of 5 stars$50.21-0.2%$54.44+8.4%+39.0%$17.96B$2.26B173.142,200News CoveragePositive NewsJEFJefferies Financial Group4.4563 of 5 stars$70.89-0.8%$81.67+15.2%+88.7%$14.57B$9.63B30.307,564DOCHealthpeak Properties4.7594 of 5 stars$19.90+1.2%$24.08+21.0%+59.3%$13.92B$543.46M42.34200 Related Companies and Tools Related Companies Ares Management Competitors Robinhood Markets Competitors Blue Owl Capital Competitors Texas Pacific Land Competitors VICI Properties Competitors Brookfield Asset Management Competitors TPG Competitors The Carlyle Group Competitors Jefferies Financial Group Competitors Healthpeak Properties Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:NMR) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nomura Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nomura With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.